Navigation Links
Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
Date:1/9/2008

SAN DIEGO, Jan. 9 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced positive results from a single dose Phase 1a clinical trial of APD791 and the initiation of a multiple dose Phase 1b clinical trial to further evaluate the compound's safety, pharmacokinetics and pharmacodynamics. APD791 is Arena's internally discovered oral drug candidate intended for the treatment of arterial thrombosis.

The Phase 1a trial was a randomized, placebo-controlled, double-blind, single-ascending dose trial in 90 healthy male and female volunteers. Doses originally intended for study ranged from 1 mg to 160 mg, but due to excellent tolerability the maximum dose was increased to 320 mg. Doses were well tolerated, without any dose related adverse events, such that a maximum tolerated dose could not be defined despite achieving high concentrations in blood. APD791 was rapidly absorbed and exposures were generally related to dose. Terminal half-life (t1/2) of the parent plus active metabolites was also related to dose, and was approximately 11 hours at the higher doses. Dose dependent inhibition of serotonin-mediated amplification of platelet aggregation was demonstrated starting at the 1 mg dose, supporting APD791 preclinical data and establishing initial clinical validation of APD791's novel mechanism of action.

Based on the positive Phase 1a results, a Phase 1b trial was initiated. The Phase 1b trial is a randomized, placebo-controlled, double-blind, multiple-ascending dose trial in up to 50 healthy male and female volunteers between the ages of 19 and 45 years old. In addition to evaluating APD791's safety and tolerability profile, the trial will also evaluate the pharmacokinetics and pharmacodynamics of multip
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
4. Vion Pharmaceuticals Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed AML
5. Fovea Pharmaceuticals Receives Orphan Drug Designation from EC for RdCVF for the Treatment of Retinitis Pigmentosa
6. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
7. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
8. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
9. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
10. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
11. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... -- Mauna Kea Technologies (Euronext: MKEA, ... endomicroscopy platform, announced today it has obtained approval ... Health, Labor and Welfare (MHLW) for its unique ... miniprobe.   Used during endoscopy procedures, ... of a fiber-optic microscope that is small enough ...
(Date:7/6/2015)... July 6, 2015   BioClinica®, Inc ., ... today announced that it has acquired a leading ... , Inc. (Medici).  The acquisition includes affiliates ... Medici also provides a lost-to-follow-up patient locate service ...  Together with Medici, BioClinica will offer ...
(Date:7/6/2015)... -- Cardinal Health today announced the completion of the ... generic pharmaceuticals, over-the-counter medications and related products to retail, ... Court Square Capital Partners. The $1.115 billion acquisition was ... Headquartered in Livonia, Mich. ... approximately $450 million in 2014. There are 450 employees ...
Breaking Medicine Technology:Mauna Kea Technologies Receives Regulatory Approval for the AQ-Flex 19 Miniprobe in Japan 2Mauna Kea Technologies Receives Regulatory Approval for the AQ-Flex 19 Miniprobe in Japan 3BioClinica Acquires MediciGroup 2BioClinica Acquires MediciGroup 3Cardinal Health Completes Acquisition Of The Harvard Drug Group For $1.115 Billion 2Cardinal Health Completes Acquisition Of The Harvard Drug Group For $1.115 Billion 3
... DIEGO, Feb. 6, 2012   Neurelis, Inc. today announced ... (FDA) has cleared an Investigational New Drug application ... of NRL-1 for the treatment of acute breakthrough ... late 2011, Neurelis filed the IND based upon ...
... Association (PCMA) launched a new ad campaign in Oregon ... (PBMs).  The ad campaign – "That,s What PBMs ... , PBMs lower costs for employers, unions, and consumers ... , PBMs help patients make informed prescription drug decisions ...
Cached Medicine Technology:Neurelis Announces FDA Allowance of IND Application for NRL-1, a Novel Intranasal Diazepam Formulation 2PCMA Launches New Oregon Ad Campaign: 'That's What PBMs Do' 2
(Date:7/6/2015)... ... July 07, 2015 , ... Currently, mobile testing is ... AIDS, advances in the molecular diagnostic technologies, wide availability of immunosuppressive drugs and ... technologies and genetic engineering also open lucrative opportunities for the market players. , ...
(Date:7/6/2015)... ... ... “ TapGlance ” was featured on NewsWatch as part of its monthly ... for iOS, Android, and Windows. Joe Toohey, the host of AppWatch and technology expert, ... users visualize what rooms will look like before they even start renovating.. , Whether ...
(Date:7/6/2015)... ... ... Shortly after opening her second practice in Signal Hill, Dr. Sue Lim ... lien basis. Dr. Lim had previously worked with Dr. Kevin Kelly, DC a ... Lim suffered with back pain herself throughout high school. Unaware of the benefits ...
(Date:7/6/2015)... ... 06, 2015 , ... The Asian-Pacific market for rheumatoid arthritis therapeutics reached a ... at a CAGR of over 3.2 percent in the years to come to hit ... mainly spurred by an anticipated launch of a number of promising pipeline candidates and ...
(Date:7/6/2015)... ... 06, 2015 , ... Longevity, the highest regarded provider of ... Urgent Care to offer on-site health screenings. These ultrasound screenings detect early signs ... and accurate and run about an hour long with same day results. , ...
Breaking Medicine News(10 mins):Health News:World Infectious Disease Testing Market Examined by VPGMarketResearch.com in In-Demand Report Available at MarketPublishers.com 2Health News:World Infectious Disease Testing Market Examined by VPGMarketResearch.com in In-Demand Report Available at MarketPublishers.com 3Health News:Create a Space with TapGlance, a Revolutionary Interior Design Application 2Health News:Respected Chiropractor Opens Office in Signal Hill/Cambodia Town and Joins Doctors on Liens 2Health News:APAC Rheumatoid Arthritis Therapeutics Market to Reach Value of USD 6.9 Billion by 2021, Says GBI Research in Its New Report Now Available at MarketPublishers.com 2Health News:Woodbridge Walk-In Offers Affordable Early Detection Health Screenings Through Longevity 2
... to have an attractive smile is the best motivator ... most receptive to oral health messages, according to a ... . , Authors Shuili Du (Simmons College), Sankar ... (Boston University) evaluated the effectiveness of an oral health ...
... expanded. And as a new study in the ... into drinking more soft drinks when retailers eliminate small ... of the soft drink, customers tend to avoid the ... Sharpe, Richard Staelin, and Joel Huber (all Duke University). ...
... Residents to Eat Right, Move More and ... Milk Their Diets, BIRMINGHAM, ... downs of different fad diets -- which seem to go in,and out of ... of three Americans -- including 25 percent of,Alabama residents -- remain overweight or ...
... in fresh,iceberg lettuce and spinach, WASHINGTON, Aug. ... Grocery Manufacturers Association (GMA), today,released the following statement ... (FDA) decision to allow ionizing radiation to be ... and fresh,spinach:, "This decision by FDA is ...
... Aug. 22 NxStage Medical,Inc. (Nasdaq: NXTM ... announced that the interim quality of life analysis ... American Society of,Nephrology Renal Week 2008 Annual Meeting ... abstract entitled "Daily Home HD (DHD),Improves Quality of ...
... Aug. 22 Republican National,Committee (RNC) Chairman Robert ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080519/RNCLOGO ), "While Barack ... uses political tactics to push poor people away ... This is yet another example of,Obama,s rhetoric not ...
Cached Medicine News:Health News:A reason to smile: New immigrants respond best to oral hygiene campaign 2Health News:The big gulp: consumers avoid extremes in soda sizes 2Health News:Message to Birmingham Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to Birmingham Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3Health News:Grocery Manufacturers Association Strongly Supports U.S. Food & Drug Administration Decision on the Irradiation of Fresh Produce for Foodborne Pathogen Control 2Health News:NxStage Announces Presentation of Data at the American Society of Nephrology's Renal Week 2008 Annual Meeting 2Health News:RNC Statement Obama and Health Care 2
VG1 ALIF (Anterior Lateral) Anterior lumbar interbody fusion. Frozen freeze-dried preservation....
Allograft implants can be easily used to repair and promote the healing of a wide variety of bone and other tissue defects....
Allograft implants can be easily used to repair and promote the healing of a wide variety of bone and other tissue defects....
Duet Lumbar Allografts are comprised of a raised cancellous inner core providing biomechanical properties for rapid healing. Specially designed instruments facilitate the insertion of Duet Allografts...
Medicine Products: